Etentamig (ABBV-383)
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of Etentamig Monotherapy or Etentamig Combinations in Subjects With Multiple Myeloma
Arms / Cohorts
Experimental:Substudy 3: Etentamig Dose Expansion
Accepting patients
Experimental:Substudy 3: Etentamig Dose Escalation
Accepting patients
Experimental:Substudy 4: Etentamig Dose Escalation
Accepting patients
Experimental:Substudy 3: Etentamig Dose Expansion
Accepting patients
Experimental:Substudy 2: Etentamig Dose Escalation
Accepting patients
Experimental:Substudy 1: Etentamig Dose Expansion
Accepting patients
Experimental:Substudy 2: Etentamig Dose Expansion
Accepting patients
Experimental:Substudy 1: Etentamig Dose Escalation
Accepting patients
Experimental:Substudy 4: Etentamig Dose Expansion
Accepting patients
Active Comparator:Substudy 3: Comparator
Accepting patients
Experimental:Substudy 4: Etentamig Dose Expansion
Accepting patients
Active Comparator:Substudy 1: Comparator
Accepting patients
Experimental:Substudy 1: Etentamig Dose Expansion
Accepting patients
Active Comparator:Substudy 2: Comparator
Accepting patients
Experimental:Substudy 2: Etentamig Dose Expansion
Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.